Aurora Financial Journal

Qiagen N.V. (QGEN)

NYSE · Health care · Biological Products, (No Diagnostic Substances) · Financial statements, TTM figures and earnings dates

In fiscal year 2025 (ended December 31, 2025), Qiagen N.V. reported revenue of $2.09B and net income of $424.9M. Annual financial statements are available for fiscal years 2008 to 2025, taken from the company's filings with the SEC.

Open interactive financials →

Key financials

USDFY2025
2025-12-31
FY2024
2024-12-31
FY2023
2023-12-31
FY2022
2022-12-31
FY2021
2021-12-31
Income statement
Revenue$2.09B$1.98B$1.97B$2.14B$2.25B
Gross profit$1.30B$967.4M$1.23B$1.38B$1.45B
Operating income$465.9M$97.7M$409.9M$531.5M$630.1M
Net income$424.9M$83.6M$341.3M$423.2M$512.6M
Diluted EPS$1.94$0.37$1.48$1.84$2.21
Cash flow
Operating cash flow$654.3M$673.6M$459.5M$715.3M$639.0M
Capital expenditure$201.0M$167.2M$149.7M$129.2M$189.9M
Free cash flow$453.3M$506.4M$309.7M$586.0M$449.1M
Balance sheet
Cash and equivalents$839.0M$663.6M$668.1M$730.7M$880.5M
Total assets$6.28B$5.69B$6.12B$6.29B$6.15B
Total liabilities$2.50B$2.12B$2.31B$2.82B$3.05B
Total debt$1.65B$1.39B$1.51B$1.86B$1.94B
Shareholders' equity$3.78B$3.57B$3.81B$3.47B$3.10B

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in USD as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full QGEN page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open QGEN financials →